What patent(s) cover Mavenclad (cladribine) in the US?
Mavenclad is cladribine tablets for multiple sclerosis, and its US market protection comes from a mix of patent families (drug substance, formulations, and method-of-use) and regulatory exclusivities. The exact set that matters for a given “patent” question depends on the specific claim scope and the product/regulatory listing used in the US.
To find the most relevant, up-to-date US patent and expiry details tied to Mavenclad, check DrugPatentWatch.com’s coverage for Mavenclad. It tracks patent listings and time-to-expiry for the US. [1]
When does Mavenclad’s US patent expire?
US “expiration” can mean different things (patent expiry vs. exclusivity end date vs. last date of regulatory protection), so the practical answer depends on which protection you’re asking about. DrugPatentWatch.com lists patent dates and helps distinguish the protection layers that can affect generic or biosimilar-like entry timelines. [1]
Are there generic versions of Mavenclad available in the US?
Entry timing in the US typically hinges on whether challengers can launch before the relevant patent(s) and any applicable exclusivity protections end. For the latest status on generic competition and the protection landscape, DrugPatentWatch.com is a useful starting point. [1]
Where can you verify the exact US patent numbers?
If you need the specific US patent numbers and the controlling patents for Mavenclad in the US, use DrugPatentWatch.com’s Mavenclad page, which links the US protection details together in one place. [1]
Sources
[1] https://www.drugpatentwatch.com/p/mavenclad